MItral Regurgitation Risk Assessment and CLinical ModElling
Launched by SUN YAT-SEN UNIVERSITY · Mar 13, 2025
Trial Information
Current as of May 09, 2025
Recruiting
Keywords
ClinConnect Summary
The MItral Regurgitation Risk Assessment and CLinical ModElling (MIRACLE) study is looking into mitral regurgitation (MR), which is a heart condition where the heart's mitral valve doesn't close properly, leading to blood leaking backward into the heart. This condition can lead to serious issues like heart failure if not treated. The trial aims to identify important risk factors that affect patients with moderate to severe MR, helping doctors make better decisions about patient care.
To participate in this study, you need to be an adult over 18 years old who has been diagnosed with at least moderate MR during a hospital stay. Unfortunately, if someone is unable to give written consent for their participation, they won't be able to join. If you or a loved one qualifies, you can expect to be part of a research effort that may improve future treatment for this heart condition. The study is currently recruiting participants, and everyone's involvement could contribute to important findings in heart health.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients diagnosed with ≥ moderate mitral regurgitation during hospitalization.
- • Aged over 18 yrs.
- Exclusion Criteria:
- • Patients unable to provide written consent.
About Sun Yat Sen University
Sun Yat-sen University, a prestigious institution located in Guangzhou, China, is dedicated to advancing medical research and healthcare innovations. As a leading clinical trial sponsor, the university leverages its extensive academic resources and collaboration with top-tier medical professionals to conduct rigorous clinical studies. Committed to improving patient outcomes and contributing to global health knowledge, Sun Yat-sen University focuses on a wide range of therapeutic areas, employing cutting-edge methodologies to ensure the integrity and efficacy of its research initiatives. Through its clinical trials, the university aims to foster scientific advancements and enhance the quality of care provided to patients both locally and internationally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Guangzhou, Guangdong, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported